Chinook Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KDNY research report →
About the company
Chinook Therapeutics, Inc. , a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials.
- CEO
- Eric L. Dobmeier
- IPO
- 2020
- Employees
- 214
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $2.71B
- P/E
- -14.07
- P/S
- 441.93
- P/B
- 5.88
- EV/EBITDA
- -16.03
- Div Yield
- 0.00%
- Gross Margin
- 71.90%
- Op Margin
- -3020.28%
- Net Margin
- -3012.65%
- ROE
- -41.23%
- ROIC
- -35.04%
- Revenue
- $6.13M · -88.13%
- Net Income
- $-184,615,000 · -82.24%
- EPS
- $-2.87 · -29.28%
- Op Income
- $-185,083,000
- FCF YoY
- -13.87%
- 52W High
- $40.51
- 52W Low
- $18.34
- 50D MA
- $36.70
- 200D MA
- $26.37
- Beta
- 0.67
- Avg Volume
- 2.04M
Get TickerSpark's AI analysis on KDNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 23 | Thomas Dolca | sell | 13,300 |
| Aug 11, 23 | Thomas Dolca | sell | 23,522 |
| Aug 11, 23 | Thomas Dolca | sell | 5,948 |
| Aug 11, 23 | Thomas Dolca | sell | 13,300 |
| Aug 11, 23 | Oxtoby Andrew | sell | 160,000 |
| Aug 11, 23 | Oxtoby Andrew | sell | 40,000 |
| Aug 11, 23 | Krishnan Mahesh | sell | 4,401 |
| Aug 11, 23 | Krishnan Mahesh | sell | 26,600 |
| Aug 11, 23 | Krishnan Mahesh | sell | 1,275 |
| Aug 11, 23 | King Andrew James | sell | 60,000 |
Our KDNY coverage
Recent articles, reports, and earnings notes.
No research on KDNY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KDNY report →Similar companies
Peers in the same neighborhood.